The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis
Insights on pipeline segments
As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are being developed to be administered by topical route, 17.0% are being developed to be administered by oral route, 17.0% are being developed to be administered by intravenous route and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral mucositis pipeline is not disclosed.
Various Companies in the pipeline received Designations from theUSFDA for the development of Oral Mucositis Therapeutics Pipeline
The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis. In November 2015, USFDA granted Fast Track designation to Brilacidin for the treatment of oral mucositis.
Many companies are involved in the development of drugs for the oral mucositis therapeutics pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one drug candidate in Discovery stage of development.
Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals
Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)